SG2918 for relapsed or refractory multiple myeloma
Part of Blood & lymphatic, Cancer, Heart & circulation, Immune system & allergy clinical trials.
This trial tests a new drug called SG2918 for people with multiple myeloma that has come back or stopped responding to treatment. It aims to see if the drug is safe and possibly effective.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 18 to 80 years old.
- You have multiple myeloma that has come back or is not responding to treatment.
- You are in generally fair health (able to do light activity).
- You have not had certain other cancers or serious health problems in the last 5 years.
- You are willing to use birth control during and for 7 months after treatment.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new drug called SG301 added to standard treatments (pomalidomide and dexamethasone) for people with multiple myeloma that came back or got worse after prior therapy. It may help if you have tried lenalidomide and a proteasome inhibitor but your cancer is still active.
This Phase 1 trial tests a new drug called RO7851624 in patients whose multiple myeloma has come back or stopped responding to prior treatments. The goal is to understand how safe and effective this drug is.
This early-phase trial tests an experimental drug called IMV102 for people with multiple myeloma that has come back or stopped responding to at least 3 prior treatments. The study aims to see if IMV102 is safe and how well it works.
This trial tests a new drug called LBL-034 in people with multiple myeloma that has come back or stopped responding to treatment. The goal is to see if it is safe and effective.
This trial tests an experimental drug called JNJ-79635322 for people with multiple myeloma that has come back or hasn't responded to at least three previous treatments, including a PI, an IMiD, and a CD38-targeted antibody. The goal is to see if this new drug can help control the disease.
This trial tests a new drug called MBS314 for people whose multiple myeloma has returned or stopped responding to other treatments. The goal is to see if MBS314 can help shrink or control the myeloma.
Hear when a new Relapsed/Refractory Multiple Myeloma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.